Digestive Diseases and Sciences

, Volume 45, Issue 7, pp 1462–1464

Saccharomyces boulardii in Maintenance Treatment of Crohn’s Disease

Authors

  • Mario Guslandi
    • Gastroenterology UnitS. Raffaele Hospital
  • Gianni Mezzi
    • Gastroenterology UnitS. Raffaele Hospital
  • Massimo Sorghi
    • Gastroenterology UnitS. Raffaele Hospital
  • Pier Alberto Testoni
    • Gastroenterology UnitS. Raffaele Hospital
Article

DOI: 10.1023/A:1005588911207

Cite this article as:
Guslandi, M., Mezzi, G., Sorghi, M. et al. Dig Dis Sci (2000) 45: 1462. doi:10.1023/A:1005588911207

Abstract

The possible role of Saccharomyces boulardii, a nonpathogenic yeast with beneficial effects on the human intestine, in the maintenance treatment of Crohn’s disease has been evaluated. Thirty-two patients with Crohn’s disease in clinical remission (CDAI < 150) were randomly treated for six months with either mesalamine 1 g three times a day or mesalamine 1 g two times a day plus a preparation of Saccharomyces boulardii 1 g daily. Clinical relapses as assessed by CDAI values were observed in 37.5% of patients receiving mesalamine alone and in 6.25% of patients in the group treated with mesalamine plus the probiotic agent. Our results suggest that Saccharomyces boulardii may represent a useful tool in the maintenance treatment of Crohn’s disease. However, in view of the product’s cost, further controlled studies are needed to confirm these preliminary data.

Crohn’s diseasemesalamineprobioticsrelapsesSaccharomyces boulardii

Copyright information

© Plenum Publishing Corporation 2000